We report a patient with CML who developed a reversible dilated cardiomyopathy with cardiac failure following 10 months of IFN therapy. Despite the previous cardiomyopathy, he tolerated subsequent allogeneic BMT without any adverse cardiac events. Reversible IFNinduced cardiomyopathy should not be considered a contraindication to bone marrow transplantation. Keywords: cardiomyopathy; CML; allogeneic BMT; IFN Complete haematological responses are documented in 80% of patients with early chronic phase CML treated with IFN and up to 58% of patients achieve a cytogenetic response with prolongation of survival. Five-year survival rates of 90, 88 and 76% for complete, partial and minor cytogenetic responders, respectively, have been reported. 1 IFN has a relatively high side-effect profile but only occasional cardiovascular toxicity has been reported. 2 The most common presentations are cardiac arrythmias, ischaemic heart disease and dilated cardiomyopathy. Cardiovascular toxicity appears to be independent of the dose or duration of IFN, and in most patients is reversible upon stopping the IFN except in those developing ischaemic cardiac events.
1
IFN has a relatively high side-effect profile but only occasional cardiovascular toxicity has been reported. 2 The most common presentations are cardiac arrythmias, ischaemic heart disease and dilated cardiomyopathy. Cardiovascular toxicity appears to be independent of the dose or duration of IFN, and in most patients is reversible upon stopping the IFN except in those developing ischaemic cardiac events. [3] [4] [5] We describe a patient receiving IFN for CML who developed a dilated cardiomyopathy which reversed following discontinuation of the drug. He underwent subsequent successful high-dose chemotherapy and allogeneic BMT without cardiac complications.
Case report
A 32-year-old man presented in September 1993 with easy bruising and splenomegaly. Cardiovascular examination and chest radiography were normal. His blood count was suggestive of CML with Hb 113g/l, platelet count 155 × 10 He was treated with hydroxyurea and IFN was escalated to 8 MU daily. A major cytogenetic response was documented after 5 months therapy with three of 20 (15%) metaphases Ph chromosome positive.
After 9 months on IFN the patient developed shortness of breath on exertion. He had evidence of cardiac failure with a tachycardia of 100 per min, BP 110/72, elevated JVP and third and fourth heart sounds. The examination was otherwise normal.
Lateral ischaemia was present on ECG. Chest radiograph showed cardiomegaly with a cardiothoracic ratio of 18.5/33, and pulmonary venous congestion. Echocardiograph showed a dilated left ventricle (70 mm in end diastole, normal Ͻ55 mm) with severe impairment of systolic function. Fractional shortening was 15% (normal 28-44). Serial cardiac enzymes were normal. There was no history of alcohol intake, viral prodrome or family history of cardiomyopathy.
A diagnosis of dilated cardiomyopathy was made. IFN was stopped and the patient treated with digoxin, frusemide and captopril, with rapid resolution of symptoms. An echocardiograph 6 weeks later revealed some improvement in cardiac function. Over the following 3 months echocardiography showed further improvement in left ventricular size and contractility (59 mm in end diastole and fractional shortening of 22%). Captopril was continued.
Five months after stopping the IFN his white count was 26 × 10 At this stage his exercise tolerance was normal. The ECG was normal and his heart size at the upper limit of normal on chest radiograph. Left ventricular systolic function was at the lower limits of normal. The patient proceeded to allogeneic BMT from his HLA-compatible sister. Conditioning was with BU 4 mg/kg/day for 4 days and CY 60 mg/kg/day for 2 days, with CsA and MTX for GVHD prophylaxis. The transplant was tolerated without development of cardiac complications. Chest radiograph remained normal and echocardiogram showed further improvement in ventricular function. Post-BMT, his exercise tolerance remained normal.
Twenty months from BMT, the patient remains alive and well. His bone marrow is normal, with a normal female karyotype and no evidence of the bcr-abl transcript by reverse transcriptase PCR.
Discussion
Cardiovascular complications secondary to IFN have been previously reported. Early clinical trials of IFN were temporarily suspended after four patients died of acute myocardial infarction, however a direct cause and effect was not established. 6 Subsequently three different types of IFNrelated cardiovascular toxicity have been reported: arrythmia, ischaemia and cardiomyopathy. Arrythmia and cardiomyopathy are considered potentially reversible.
In a review of 44 patients with IFN cardiotoxicity (eight received interferon gamma), 25 suffered arrhythmia, nine myocardial infarction/ischaemia, five cardiomyopathy, two sudden death, one atrio-ventricular block and one congestive heart failure. 7 Cardiotoxicity was not related to the duration of treatment, the single daily dose, or to the total amount of IFN. None of the patients who developed cardiomyopathy had known heart disease, but underlying heart disease was present in 12 of the 34 patients who developed IFN-induced arrhythmia or ischaemia. 7 Increased oxygen demand from IFN-induced tachycardia and fever may precipitate infarction or arrhythmia in an already compromised myocardium. An alternative mechanism is needed for the reversible cardiomyopathy that occurs without previously known heart disease. The left ventricular ejection fraction declined by greater than 10% in five of 11 patients with chronic viral hepatitis receiving IFN for 1 month. This reversed in three of the five patients after discontinuation of IFN. It has been suggested that IFN may either inhibit cardiac cells, increase peripheral vascular resistance or damage the myocardium by an immunologically mediated mechanism.
38 IFN toxicity appears to be the most likely cause for the cardiomyopathy in our patient, given the temporal relation between IFN therapy and the development and resolution of clinical signs and symptoms, and lack of other causes of cardiomyopathy. CY can cause acute reversible cardiotoxicity including pericardial effusion, myocarditis or heart failure. 9 In one study, prior congestive heart failure or reduced ejection fraction were the only predictors of development of clinical cardiotoxicity following high-dose CY. 10 Our patient did not develop transplant-induced cardiotoxicity, supporting the reversibility of IFN-related cardiomyopathy.
This is the first report of successful allogeneic BMT following symptomatic cardiomyopathy induced by IFN. It suggests that IFN-induced cardiomyopathy is reversible and may not be a contraindication to allogeneic BMT or exposure to further potentially cardiotoxic therapy.
